Clinical Impact of New Data from Boston 2014

March 3-6, 2014; Boston, Massachusetts
In this Expert Analysis, Joseph J. Eron, Jr., MD; Joel E. Gallant, MD, MPH; and Andrew R. Zolopa, MD, provide an in-depth review of the most clinically relevant new data presented at the 2014 Conference on Retroviruses and Opportunistic Infections on the management of HIV and other key topics, along with downloadable slides.
Joseph J. Eron, Jr., MD
Joel E. Gallant, MD, MPH
Andrew R. Zolopa, MD
Physicians: maximum of 2.0 AMA PRA Category 1 Credits
Released: April 30, 2014 Expiration: April 29, 2015

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Integrate new data from phase III clinical trials of antiretroviral regimens in first-line therapy and as switch strategies in patients who are virologically suppressed
  • Critically appraise the latest findings on the impact of antiretroviral treatment or prophylaxis and other factors on the risk of HIV transmission
  • Apply new findings regarding cardiovascular risk, reduced bone mineral density, and depression in HIV-infected patients
  • Counsel patients regarding the results of clinical trials of direct-acting agents for HCV treatment in HCV-monoinfected and HIV/HCV-coinfected patients

Acknowledgements

Jointly sponsored by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ACHS Logo

Annenberg Center for Health Sciences at Eisenhower
39000 Bob Hope Dr
Dinah Shore Bldg.
Rancho Mirage, CA 92270

Alma Perez, Accreditation Specialist
(760) 773-4506
(760) 773-4550 (Fax)
ce@annenberg.net
http://www.annenberg.net/

Educational grant provided by:
AbbVie
Gilead Sciences
Merck & Co., Inc.
ViiV Healthcare

Information on this Educational Activity

Disclosure of Conflicts of Interest

The Annenberg Center for Health Sciences at Eisenhower (Annenberg Center) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by the Annenberg Center for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Faculty

Joseph J. Eron, Jr., MD

Professor of Medicine and Epidemiology
University of North Carolina School of Medicine
Director, AIDS Clinical Trials Unit
University of North Carolina
Chapel Hill, North Carolina

Joseph J. Eron, Jr., MD, has disclosed that he has received funds for research support from GlaxoSmithKline; served as a consultant for AbbVie, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline/ViiV, Merck, Tibotec/Janssen, and Tobira; and served on the data and safety monitoring board for Vertex.
Joel E. Gallant, MD, MPH

Medical Director of Specialty Services
Southwest CARE Center
Santa Fe, New Mexico
Adjunct Professor of Medicine
Division of Infectious Diseases
Johns Hopkins University School of Medicine
Baltimore, Maryland

Joel E. Gallant, MD, MPH, has disclosed that he has received consulting fees from Bristol-Myers Squibb, Gilead Sciences, Merck, Theratechnologies, and ViiV and funds for research support from AbbVie, Bristol-Myers Squibb, Gilead Sciences, Janssen, Merck, Sangamo, and ViiV.
Andrew R. Zolopa, MD

Professor of Medicine
Director
, Stanford Positive Care Program
Principal Investigator, Stanford AIDS Clinical Trials Unit
Stanford University School of Medicine
Stanford, California

Andrew R. Zolopa, MD, has disclosed that he has received royalties from McGraw-Hill, served as a consultant for Gilead Sciences and Janssen, and received funds for research support from Gilead Sciences, Janssen, Pfizer, and ViiV.

Staff

Taryn O’Loughlin Gross, PhD

Senior Managing Editor

Taryn O’Loughlin Gross, PhD, has no financial relationships to disclose.
Edward King, MA

Chief Innovation Officer

Edward King, MA, has no significant financial relationships to disclose.
Krista Marcello

Associate Managing Editor

Krista Marcello has no significant financial relationships to disclose.
Elaine P. Seeskin

Senior Managing Editor

Elaine Seeskin has no significant financial relationships to disclose.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

The following planners and managers, Laura Excell, ND, NP, MS, MA, LPC, NCC; Trace Hutchison, PharmD; Samantha Mattiucci, PharmD, CCMEP; and Jan Schultz, RN, MSN, CCMEP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Charles E. Willis, MBA, disclosed that he consults for Pfizer, Inc.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Annenberg Center, Postgraduate Institute for Medicine (PIM), Clinical Care Options, and activity supporters do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the Annenberg Center, PIM, Clinical Care Options, and activity supporters. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This activity is intended for physicians and other healthcare professionals involved in the care of HIV-infected patients.

Goal

The goal of this activity is to improve participants’ competence in translating the most clinically significant and relevant data from the 2014 Conference on Retroviruses and Opportunistic Infections into practical management strategies for HIV-infected patients.

Physician Continuing Medical Education

Accreditation Statement

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC. The Annenberg Center for Health Sciences at Eisenhower is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

The Annenberg Center for Health Sciences at Eisenhower designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 2.0 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from April 30, 2014, through April 29, 2015:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 70% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Related Content

Michelle Sherman, RPh, FASCP, FACA, AAHIVP, discusses how pharmacists can improve HIV care outcomes through testing, prevention, and MTM services

Michelle J. Sherman, RPh, FASCP, FACA, AAHIVP Released: August 20, 2019

Downloadable audio from Jürgen K. Rockstroh, MD, with analysis of key new HIV data from IAS 2019 on NTD risk in pregnancy, PrEP, and emerging ART options

Jürgen K. Rockstroh, MD Released: August 20, 2019

Rapid ART initiation for HIV, practical examples from San Francisco and New Orleans, with Monica Gandhi and Jason Halperin. From Clinical Care Options

Monica Gandhi, MD, MPH Jason Halperin, MD, MPH Released: August 19, 2019

Jonathan Appelbaum, MD, FACP, AAHIVS, provides expert commentary on the challenges with care coordination for older patients living with HIV

Jonathan Appelbaum, MD, FACP, AAHIVS Released: August 15, 2019

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?